

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Jinhai Medical Technology Limited**

**今海醫療科技股份有限公司**

*(Incorporated in the Cayman Islands with members' limited liability)*

**(Stock Code: 2225)**

### **APPOINTMENT AND RESIGNATION OF DIRECTORS**

#### **APPOINTMENT AND RESIGNATION OF DIRECTORS**

The Board is pleased to announce that Mr. Jiang Jiangyu is appointed as a non-executive Director of the Company with effect from 28 January 2025 while Mr. Dai Yong has resigned as an executive Director of the Company with effect from 28 January 2025.

#### **APPOINTMENT OF DIRECTOR**

The Board of Directors (the “**Board**”) of Jinhai Medical Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Jiang Jiangyu is appointed as a non-executive director of the Company (“**Director**”) with effect from 28 January 2025. Mr. Jiang is also appointed as the vice chairman of the Board.

Mr. Jiang Jiangyu (蔣江雨先生) (“**Mr. Jiang**”), aged 42, has extensive experience in the information technology industry and business management. Mr. Jiang obtained a bachelor’s degree in administration at the Huazhong University of Science and Technology (華中科技大學) in June 2006. Mr. Jiang also graduated from the Shanghai Advanced Institute of Finance (上海高級金融學院) of the Shanghai Jiao Tong University (上海交通大學) with a master’s degree in executive business administration in June 2018.

From August 2010 to April 2012, Mr. Jiang worked at the sales department of Trend Micro (China) Incorporated (趨勢科技(中國)有限公司). From June 2012 to February 2014, Mr. Jiang worked as a deputy director of sales of the Eastern China region of Kaspersky Technology Development (Beijing) Co., Ltd. (Shanghai branch) (卡巴斯基技術開發(北京)有限公司(上海分公司)). From July 2014 to December 2017, Mr. Jiang worked as a president of Shanghai Lucai Internet Technology Company Limited\* (上海路彩互聯網科技有限公司). Since January 2018, Mr. Jiang has been a president of Shanghai Shunma Data Technology Company Limited\* (上海舜馬數據科技有限公司).

Mr. Jiang has also been a non-executive Director and a member of the remuneration committee of the Company from 19 July 2019 to 6 August 2021.

Mr. Jiang served as the deputy secretary general of Shanghai Information Security Trade Association (上海市信息安全行業協會) from 2013 to 2016 and is currently the deputy chairman of Ningbo Chamber of Commerce in Shanghai (上海市寧波商會). Since December 2018, Mr. Jiang has been a deputy chairman of the Information Technology Chamber of Commerce of Shanghai Federation of Industry and Commerce (上海市工商業聯合會信息產業商會).

As at the date of this announcement and within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“SFO”), Mr. Jiang holds 25,850,000 share options granted under the share option scheme of the Company adopted on 29 December 2023 (being the number of share options adjusted following the approval of the subdivision of the shares of the Company by the shareholders of the Company on 22 November 2024). Each of the 25,850,000 share options entitles him to subscribe for one ordinary share of the Company. Save as disclosed herein, Mr. Jiang does not hold any other interest in the shares of the Company.

Mr. Jiang (i) does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company and (ii) does not hold any other directorship in listed public companies whether in Hong Kong or overseas in the last three years preceding the date of this announcement.

There is a one-year service contract entered into between the Company and Mr. Jiang who is subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association of the Company.

Mr. Jiang will receive a fixed director’s fee of HK\$504,000 per annum. His remuneration is determined by the Board with reference to his roles and responsibilities with the Company and prevailing market conditions.

Save as disclosed above, there is no information in relation to the appointment of the Director that is required to be disclosed according to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and there are no other matters that need to be brought to the attention of the shareholders of the Company.

## **RESIGNATION OF DIRECTOR**

The Board further announces that Mr. Dai Yong (“**Mr. Dai**”) has tendered his resignation as an executive Director with effect from 28 January 2025 due to his other business commitments which require more of his time and dedication. Immediately upon the taking effect of his resignation, Mr. Dai also resigned as the chief operation officer of the Group.

Mr. Dai has confirmed that as at the date of this announcement, (i) he does not have any claim against the Company in respect of his resignation; (ii) he does not have any disagreement with the Board; nor (iii) there are any other matters in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board would like to extend its warm welcome to Mr. Jiang to the Board and to extend its sincere gratitude to Mr. Dai for his valuable contributions towards the Company during his tenure of office.

By Order of the Board  
**Jinhai Medical Technology Limited**  
**Chen Guobao**  
*Chairman of the Board and executive Director*

Hong Kong, 28 January 2025

*As at the date of this announcement, the Board comprises eight Directors, of which three are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping; two are non-executive Directors, namely Mr. Jiang Jiangyu and Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.*

\* *For identification purposes only*